This is a list of investigational antipsychotics, or drugs that are currently under development for clinical use as antipsychotics for the treatment of schizophrenia and other psychotic disorders but are not yet approved. Psychotic disorders include schizophrenia, schizoaffective disorder, and others such as psychotic depression, Parkinson's disease psychosis, and Alzheimer's disease psychosis. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". This list was last comprehensively updated in June 2026. It is likely to become outdated with time.
Under development
Preregistration Olanzapine long acting injectable (mdc-TJK; TEV-749; TV-44749) – dopamine D1 receptor antagonist, dopamine D2 receptor antagonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia [1] Roluperidone (CYR-101; MIN-101; MT-210) – serotonin 5-HT2A receptor antagonist, sigma σ2 receptor antagonist, and other actions – schizophrenia [2]
Phase 3 Brilaroxazine (RP-5000; RP-5063; oxaripiprazole) – dopamine D2 receptor partial agonist, serotonin 5-HT2A receptor antagonist, and other actions – schizophrenia [3] Direclidine (HTL-0016878; NBI-1117568; NBI-568) – muscarinic acetylcholine M4 receptor agonist – schizophrenia [4] Evenamide (EA-8001; NW-3509; NW-3509A) – voltage-gated sodium channel (VGSC) blocker – schizophrenia [5] Iclepertin (BI-425809) – glycine transporter 1 (GlyT1) inhibitor – schizophrenia [6] N-Methylamisulpride (LB-102) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT2B receptor antagonist, and serotonin 5-HT7 receptor antagonist – schizophrenia [7] Remlifanserin (ACP-204) – serotonin 5-HT2A receptor inverse agonist – psychotic disorders [8] Risperidone extended release (LYN-005) – dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist – schizophrenia, schizoaffective disorder [9] Ulotaront (SEP-363856; SEP-856) – trace amine-associated receptor 1 (TAAR1) agonist and serotonin 5-HT1A receptor agonist – schizophrenia [10] Valbenazine (Dysval; Ingrezza; MT-5199; NBI-98854; Remleas) – vesicular monoamine transporter 2 (VMAT2) blocker and monoamine depleting agent – schizophrenia [11] Xanomeline enteric coated (BMS-986519; KarX-EC; LY-246708; Memcor; NNC-110232) – muscarinic acetylcholine M1 and M4 receptor agonist – psychotic disorders [12] Xanomeline/trospium chloride (BMS-986510; Cobenfy; KarXT; trospium/LY-246708; trospium/xanomeline) – combination of xanomeline (muscarinic acetylcholine M1 and M4 receptor agonist) and trospium chloride (peripherally selective non-selective muscarinic acetylcholine receptor antagonist) – psychotic disorders [13]
Phase 2/3 AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist – schizophrenia [14] Deudextromethorphan (AVP-786; CTP-786; d-DM; d6-DM; deudextromethorphan/quinidine; deuterated dextromethorphan; deuterated-DM) – combination of deudextromethorphan (sigma receptor agonist, ionotropic glutamate NMDA receptor antagonist, serotonin reuptake inhibitor, other actions) and quinidine (CYP2D6 inhibitor) – schizophrenia [15] Sodium benzoate (benzoate; Clozaben; NaBen; SND-51; SND-11; SND-12; SND-13; SND-14; Tannquilynne; Ω-NaBen) – D-amino acid oxidase inhibitor – schizophrenia [16]
… excerpt ends here. Continue reading the full article.
